Press Release

  View printer-friendly version

« Back

Collegium Announces Poster Presentations for Xtampza™ ER at American Pain Society Meeting

May 11, 2016 at 6:01 AM EDT

CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, in an elderly population at the American Pain Society Meeting, taking place May 11-14, 2016 in Austin, Texas.

The poster titled, “Tolerability, Safety, and Efficacy of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain,” is a post hoc analysis of data from 88 patients aged 65 or older, with chronic low back pain, who were treated with Xtampza ER as part of a Phase 3 randomized withdrawal, double-blind, placebo-controlled, enriched-enrollment, parallel-group, multicenter, 12-week clinical study.

Collegium also supported a poster that will be presented by Inflexxion, Inc. titled, “Relative Abuse of Abuse-deterrent Formulations via Alternative Oral Routes,” which examined prevalence of alternate oral abuse involving product manipulation (e.g., chewing) versus swallowing dosage forms whole.  Data from January 2009 through March 2015 were examined from the ASI-MV®, a computerized, clinical interview for adults in substance abuse treatment, which captures self-report of past 30-day abuse of prescription opioid products and routes of administration.

Both posters will be presented at the American Pain Society poster session on Thursday, May 12th.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER


Xtampza ER is an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For Important Safety Information Visit,

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our products and product candidates; the existence of any patent infringement or similar litigation relating to any of our products or product candidates, and costs and delays associated with such litigation; the size and growth potential of the markets for our product and product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product and product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015, and those risks described from time to time in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Douglas Carlson
Vice President, Corporate Development

Primary Logo

Collegium Pharmaceutical, Inc